Abstract 2044P
Background
BSI are a frequent and severe complication in cancer. Recent changes in oncological treatment, supportive care and development of new antimicrobial therapies could have affected its epidemiology, management and outcomes. Our aim is to describe clinical and microbiological features, antibiotic therapy, outcomes and mortality-related risk factors of BSI in cancer patients.
Methods
We performed a retrospective, observational, unicentric study. Microbiologically-confirmed BSI episodes in cancer patients between January 2017 and December 2021 were collected. We analysed clinical and microbiological data, empirical antibiotic treatment (EAT) and outcomes. A binary logistic regression model was used to detect variables related to 7 and 30-days mortality. P values <0.05 were considered significant.
Results
438 episodes of BSI were documented in 362 patients. Most frequent neoplasms were pancreatobiliary (25.1%), colorectal (16.9%), lung (11.9%) and breast (9.1%) tumours. 78.1% were metastatic. 72.1% had received chemotherapy in the previous month. The most common sources of BSI were vascular catheters (26.9%), cholangitis (23.1%) and other abdominal infections (22.8%). Gram-negative bacteria (GNB) were isolated in 60.3% of cases and Gram-positive bacteria in 45.4%. Yeasts were isolated in 3.9% of cases. Most common organisms were E. coli (29.7%), Klebsiella spp. (15.1%), coagulase-negative staphylococcus (12.6%) and S. aureus (10.3%). Most used EAT was piperacillin/tazobactam (43.2%), followed by meropenem (18.3%), amoxicilin/clavulanic acid (16%) and vancomycin (14.8%). Adequate EAT was given to 76.3% of patients. Mortality at 7 and 30 days was 11.2% and 24.4%, respectively. Statistical analysis showed lung cancer, respiratory source, yeasts and Pseudomonas spp. as independent risk factors for 7 and 20-days mortality.
Conclusions
BSI is a severe complication associated to elevated mortality in cancer patients. Most frequent sources of BSI are vascular catheters, cholangitis and abdominal infections. Most of them occur in patients with metastatic digestive tumours and are caused by GNB. Lung cancer, respiratory infections, isolation of yeasts and Pseudomonas spp. could imply a worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06